KODIAK SCIENCES INC. Variable Lease, Cost
KODIAK SCIENCES INC. (KOD) reported Variable Lease, Cost of $3.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-31
- KODIAK SCIENCES INC. variable lease, cost for fiscal 2025 was $3.25M, a 2.11% decline from fiscal 2024.
- KODIAK SCIENCES INC. variable lease, cost for fiscal 2024 was $3.32M, a 8.24% decline from fiscal 2023.
- KODIAK SCIENCES INC. variable lease, cost for fiscal 2023 was $3.62M.
- KODIAK SCIENCES INC. variable lease, cost for fiscal 2019 was $200.00K.
| Period end | Variable Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $3.25M 10-K · filed 2026-03-31 |
| 2024-12-31 | $3.32M 10-K · filed 2026-03-31 |
| 2023-12-31 | $3.62M 10-K · filed 2026-03-31 |
| 2019-12-31 | $200.00K 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |